PPARG and rhabdomyosarcoma: Panigrahy and colleagues demonstrated PPARγ expression in tumor endothelium, reduced tumor growth and metastatic spreading of subcutaneously implanted LLC1, glioblastoma, liposarcoma, and rhabdomyosarcoma upon treatment with the PPARγ agonist rosiglitazone.